SCHEDULE 13G/A 0001104659-24-109248 0002038058 XXXXXXXX LIVE 1 Common Shares 07/29/2025 0001374339 ProMIS Neurosciences Inc. 74346M406 1920 YONGE STREET SUITE 200 TORONTO A6 M4S 3E2 Rule 13d-1(c) Shaf QIC LLC b NH 10534639.00 0.00 10534639.00 0.00 10534639.00 N 10.01 OO Consists of (i) 5,184,760 Common Shares, no par value per share (the "Common Shares") and (ii) 5,349,879 Common Shares issuable upon exercise of warrants, none of which are currently exercisable. The reported warrants contain provisions preventing their exercise to the extent that such exercise would result in the holder (together with its affiliates) obtaining greater than 9.99% of the Issuer's Common Shares (the "Beneficial Ownership Blocker"). However, the amounts reported in rows (5), (7) and (9) herein represent the number of Common Shares issuable upon exercise of the warrants in full, and do not give effect to the Beneficial Ownership Blocker. Therefore, the actual number of Common Shares beneficially owned by the Reporting Persons, after giving effect to the Beneficial Ownership Blocker, is less than the number of shares reported in rows (5), (7) and (9). The percent of class was calculated based upon 51,806,497 Common Shares of the Issuer outstanding as of July 31, 2025, as reported by the Issuer on July 31, 2025. Jonathan Shafmaster b X1 10534639.00 0.00 10534639.00 0.00 10534639.00 N 10.01 IN Consists of (i) 5,184,760 Common Shares and (ii) 5,349,879 Common Shares issuable upon exercise of warrants, none of which are currently exercisable. The reported warrants contain provisions preventing their exercise to the extent that such exercise would result in the holder (together with its affiliates) obtaining the Beneficial Ownership Blocker. However, the amounts reported in rows (5), (7) and (9) herein represent the number of Common Shares issuable upon exercise of the warrants in full, and do not give effect to the Beneficial Ownership Blocker. Therefore, the actual number of Common Shares beneficially owned by the Reporting Persons, after giving effect to the Beneficial Ownership Blocker, is less than the number of shares reported in rows (5), (7) and (9). The percent of class was calculated based upon 51,806,497 Common Shares of the Issuer outstanding as of July 31, 2025, as reported by the Issuer on July 31, 2025. ProMIS Neurosciences Inc. 1920 YONGE STREET SUITE 200 TORONTO, A6, M4S 3E2 Shaf QIC LLC 158 SHATTUCK WAY, NEWINGTON, NH, 03801 New Hampshire Y The information in Item 1 and Items 5 through 11 on the cover pages of this Schedule 13G regarding ownership as of the date of this filing is incorporated herein by reference. 10.01% 10,534,639 10,534,639 Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Shaf QIC LLC /s/ Jonathan Shafmaster 07/31/2025 Jonathan Shafmaster /s/ Jonathan Shafmaster 07/31/2025